ArticleCancers2020
Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 23 citations in OpenAlex.
- Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.Breast cancer research : BCR · 2021Trial
- Application of Hydrogel in the Capture and Detection of Circulating Tumor Cells.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Establishment and clinical value of a circulating tumor cell system based on a multi-site immune lipid magnetic sphere technique in laryngopharyngeal head and neck tumors.American journal of cancer research · 2025Article
- Label-free detection and simultaneous viability determination of CTCs by lens-free imaging cytometry.Analytical and bioanalytical chemistry · 2025Article
- Novel Isolating Approaches to Circulating Tumor Cell Enrichment Based on Microfluidics: A Review.Micromachines · 2024Review
- Liquid biopsy-based early tumor and minimal residual disease detectionMedizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
- Article
- Review
- Review
- Significance of circulating tumor cells in lung cancer: a narrative review.Translational lung cancer research · 2023Review
- How previous treatment changes the metabolomic profile in patients with metastatic breast cancer.Archives of gynecology and obstetrics · 2022Article
- Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients.Breast cancer research and treatment · 2022Article
- Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment.International journal of molecular sciences · 2022Article
- Detection of circulating tumor cells: opportunities and challenges.Biomarker research · 2022Review
- HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment.Frontiers in bioengineering and biotechnology · 2022Article
- Mitochondria dysfunction in circulating tumor cells.Frontiers in oncology · 2022Review
- Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue.Biomedicines · 2021Review
- Detection of circulating tumor cells: Advances and critical concerns.Oncology letters · 2021Review
- Article
- Cellular Mechanisms of Circulating Tumor Cells During Breast Cancer Metastasis.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
Detection of circulating tumor cells (CTC) can distinguish between aggressive and indolent metastatic disease in breast cancer patients and is thus considered an independent, negative prognostic factor. A clear decline in CTCs is observed in patients who respond to systemic therapy. Nevertheless, CTCs can decrease in patients experiencing disease progression during systemic therapy, too. This study aims to determine the differences between CTC decline in patients responding to therapy and those in whom disease is progressing. Therefore, CTC values were compared at the start and after one cycle of a new line of systemic therapy. In all, 108 initially CTC-positive patients (with ≥5 intact CTCs in 7.5 mL blood) were enrolled in this study and intact and apoptotic CTCs were measured via the CellSearch
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.